MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Merck KGaA (MKGAF)
Finance & Acquisitions: Merck KgaA
Parents
Merck KGaA (MKGAF)
Children
2012: Merck KGaA Signs $550 Million Cancer Pact With Threshold Pharmaceuticals, Inc. (THLD) (2012)
2020: Round led by Casdin Capital and by Danaher Life Sciences, Agilent Technologies, Merck KGaA, through its corporate venture arm, M Ventures, LSP, the Bpifrance Large Venture Fund and Illumina Ventures.
2021: Merck KGaA Completes Millipore Acquisition and Launches New Merck Millipore Division
2022: Series A funding round led by Safar Partners and joined by Horizons Ventures and M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany), among others
2025: Merck KGaA to acquire SpringWorks Therapeutics for $3.9 billion
2025: Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
2026: Merck KGaA throws down $11.3B for Bio-Techne in its biggest deal since 2015 Sigma-Aldrich buy
2026: Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)
M Ventures
MilliporeSigma
Revenue: 17.53 billion EUR (2020)
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)*
Jumps
Key People: Merck KgaA
Organization & Developments: Merck KgaA